Good try, but Auryxia paitients were the one had not responded to Iron pills, the Roxadustat patients seem to not have that restriction. Many patients all they need is Iron pill, the Roxadustat is missing the control group. Go away
This is not good, we were over 500 a few weeks ago, now numbers are coming in with a 4 handle on it. Stock however is doing good, maybe something going on that we don't know about.
This guy was running VRX before coming to ENDP and screwing this one up. I think he is toxic and nobody should hire him anymore. Is he the careless acquisition fellow for both companies?
This company like it's younger sibling HZNP bought drugs and companies at inflated prices, and then raised the price in an absurd fashion burdening the ever increasing healthcare cost. Well it seems like game is over, when they roll back the prices as they must, they may not even be profitable. Also it is noteworthy that because of pushback from payors, they had to scheme the specialty pharmacy to push through their absurd price increases. Aster having heard the hearing on aging on April 27, I sold today, not ethical to invest in this company before, and may not be profitable investment going forward.
Why in the world you would spend $millions and test only 12 patients. What is wrong with these morons, of course they cannot get approval with 12 patients. Does anyone know why they tested only 12 patients. BMRN had 220 tested, so obviously no shortage of volunteers. Stock will be at $8 or more tomorrow, they got over $4 in cash, and other products.
These are all smoke screen, when dust settles in 2 to 3 months this stock should be trading north of $50.
The question is about protocol, it is not about any advers test results. It is standard procedure to put a hold when FDA has question, this is not necessarily a bad news.
If FDA had put a hold because there had been unusual high death rate due to drug, that would have been bad news, but if hold is because they have some question, it does not warrant the price drop we have here. This company has 30 drugs in pieline, to shave up 10% because FDA has questions to ask, it is way overdone.
Allergan with all the cash, and with inversion rule which makes smaller aquizitions favored more, VRX will have no trouble selling assets at primume prices
There is a chance of that. I think the real risk is that, can VRX maintain it's existing sales, even 90% of it's existing sales through the normal managed pharmacy channels, Vs specialty pharmacy channels they used before. I see a risk there, but their guidance ( not to be relied uppon), and so far reported prescription trends indicate that situation is not as bad as feared. All in all I agree, there is risk, I would not invest money that I cannot afford to lose.
From what we hear, investors are sending in withdrawal notices to hedge funds forcing them to sell the VRX shares, every press is focused on bad news. I don't like this company for what they have done contributing to the drug inflation, but that was the past, now we have a value stock. I do not believe for a minute that bond holders will push this company to bankruptcy, they have nothing to gain by doing that, VRX has a very healthy cash flow to service it's debt many times over, they will survive and at PE of less than 3, it is hard not to see value here.Remember Imclone controversy, that drove the stock from 50 to single digit only to come back and be taken over at $70. Concentrate on drugs baby, they work, they sell, sales is growing, go against the negative press, the issues on hand are not bad enough to warrant such a low share price.
Nonesense, Jublia weekly TRX are going gangbusters, it has grown to 0ver TRX of 17000 in US, and over 100,000 weekly TRX in EU, do you realize how big is that. As far as not working, you need to apply the medication for about a year allowing healthy nail to grow, you will not know if it is working or not until the bad nail is grown away.